Advertisement

Topics

Eli Lilly SPARTAN phase 3 study of lasmiditan for acute treatment of migraine meets primary endpoint

06:48 EDT 7 Aug 2017 | PharmaBiz

Eli Lilly and Company announced that lasmiditan, an investigational, oral, first─in─class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second phase 3 study. At two hours

Original Article: Eli Lilly SPARTAN phase 3 study of lasmiditan for acute treatment of migraine meets primary endpoint

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly SPARTAN phase 3 study of lasmiditan for acute treatment of migraine meets primary endpoint"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...